CATALENT, INC.

(CTLT)
  Report
Delayed Nyse  -  05/25 04:05:17 pm EDT
96.69 USD   -0.07%
05/20Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winchester, Kentucky
AQ
05/17Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
AQ
05/11TRANSCRIPT : Catalent, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:40 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast

01/21/2022 | 08:16am EDT

Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2022 ended December 31, 2021, before the market open on Tuesday, February 1, 2022. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com.

A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast. The webcast replay, along with the supplemental slides, will be available for 90 days in the “Investors” section at www.catalent.com.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is the industry’s preferred partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™


© Business Wire 2022
All news about CATALENT, INC.
05/20Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winc..
AQ
05/17Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time..
AQ
05/11TRANSCRIPT : Catalent, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/04Morgan Stanley Adjusts Catalent's Price Target to $132 from $145, Keeps Overweight Rati..
MT
05/04UBS Adjusts Catalent Price Target to $145 From $155, Maintains Buy Rating
MT
05/04KeyBanc Adjusts Catalent's Price Target to $125 From $155, Keeps Overweight Rating
MT
05/03SECTOR UPDATE : Health Care Stocks Rise on Tuesday
MT
05/03SECTOR UPDATE : Health Care Advance Led Higher by Biotechs
MT
05/03SECTOR UPDATE : Health Care Stocks Advancing on Tuesday, Led Higher by Biotechs
MT
05/03SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Financials (USD)
Sales 2022 4 857 M - -
Net income 2022 481 M - -
Net Debt 2022 3 136 M - -
P/E ratio 2022 35,9x
Yield 2022 -
Capitalization 17 341 M 17 341 M -
EV / Sales 2022 4,22x
EV / Sales 2023 3,81x
Nbr of Employees 17 300
Free-Float 99,7%
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 96,76 $
Average target price 134,92 $
Spread / Average Target 39,4%
EPS Revisions
Managers and Directors
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli Vice President-Operations
Thomas P. Castellano Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
CATALENT, INC.-24.48%17 341
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494